Showing posts with label pediatric. Show all posts
Showing posts with label pediatric. Show all posts

Thursday, October 1, 2015

Children's Health:Childhood stress impacts adult health ♦ Legal drinking age of 18 tied to high school dropout rate ♦ Kids allowed to be kids make better parents

Legal drinking age of 18 tied to high school dropout rate Although there have been calls to lower the legal drinking age from 21, a new study raises the possibility that it could have the unintended effect of boosting the high school dropout rate.
Kids allowed to be kids make better parents Mothers who took on burdensome care giving roles as children -- and weren't allowed to just 'be kids' -- tend to be less sensitive to their own children's needs
Discovery provides insight into life-threatening respiratory distress in newborns St. Jude Children’s Research Hospital scientists advance understanding of intrahepatic cholestasis of pregnancy, a liver disorder that leaves infants born to affected mothers at risk for severe respiratory distress
Pediatric injuries from toppled TV sets: Risk factors, strategies for prevention After a thorough review of medical articles describing head injuries caused by toppled television sets in children, researchers assessed the risk factors associated with these events. Based on their assessment, the researchers developed strategies to prevent these injuries.
Childhood stress impacts adult health A 45-year study of nearly 7,000 people born in a single week in Great Britain in 1958 found psychological distress in childhood -- even when conditions improved in adulthood -- was associated with higher risk for heart disease and diabetes later in life.

Tuesday, May 5, 2015

Brain Research: Premature birth alters brain connections ♦ Brain scan reveals out-of-body illusion ♦ Cellular bubbles used to deliver Parkinson's meds

Brain scan reveals out-of-body illusion  Neuroscientists have created an out-of-body illusion in participants placed inside a brain scanner. They then used the illusion to perceptually 'teleport' the participants to different locations in a room and show that the perceived location of the bodily self can be decoded from activity patterns in specific brain regions.
Fuzzy thinking' in depression, bipolar disorder: New research finds effect is real People with depression or bipolar disorder often feel their thinking ability has gotten “fuzzy”, or less sharp than before their symptoms began. Now, researchers have shown in a large study that effect is indeed real – and rooted in brain activity differences that show up on advanced brain scans.
Premature birth alters brain connections Premature birth can alter the connectivity between key areas of the brain, according to a new study. The findings should help researchers to better understand why premature birth is linked to a greater risk of neurodevelopmental problems, including autistic spectrum disorders and attention deficit disorders
Cellular bubbles used to deliver Parkinson's meds directly to brain Exosomes could help with longstanding medical issues from cancer diagnosis to sophisticated research tool. Now, they could potentially help with delivering potent antioxidants into the brain of Parkinson's patients.
Study points to possible treatment for lethal pediatric brain cancer Using brain tumor samples collected from children in the United States and Europe, an international team of scientists found that the drug panobinostat and similar gene regulating drugs may be effective at treating diffuse intrinsic pontine gliomas, an aggressive and lethal form of pediatric cancer.

Monday, May 4, 2015

Possible treatment for lethal pediatric brain cancer

Using brain tumor samples collected from children in the United States and Europe, an international team of scientists found that the drug panobinostat and similar gene regulating drugs may be effective at treating diffuse intrinsic pontine gliomas (DIPG), an aggressive and lethal form of pediatric cancer. The study, published in Nature Medicine, was partially funded by the National Institutes of Health, the Department of Defense, and more than 25 nonprofit foundations devoted to finding cures for childhood brain cancer.
DIPG typically attacks children 4 to 9 years of age. Children progressively lose muscle control as the tumor rapidly attacks the pons, a region deep inside the brain that connects the brain to the spinal cord, and is difficult to reach and surgically remove. Despite radiation treatment, children usually survive for about nine months, and less than 1 percent survive longer than five years.
Six years ago, Dr. Monje started to create and share cell cultures of patients’ DIPG cells that could be studied in labs. In this study, she and her colleagues used cell cultures collected from 16 patients in the United States and Europe to search for drugs that could kill or stop the growth of DIPG cells. By performing experiments in petri dishes and with mice, they found that panobinostat, a drug designed to change the way cells regulate genes, may be effective at inhibiting DIPG growth and extending survival rates.
“It’s astounding. In only six years, scientists have gone from knowing virtually nothing about this tumor to understanding its underlying genetics and finding a potential therapy,” said Jane Fountain, Ph.D., program director, at the National Institute of Neurological Disorders and Stroke (NINDS), part of NIH. “This study epitomizes collaborative medicine at work. It took a dedicated team of international scientists working with patients, families and foundations to get to this point.”
The scientists began their work by performing high-throughput screening experiments, an advanced method for rapidly searching for effective compounds. The screening simultaneously tested 83 known or potential cancer drugs on each of the DIPG cell lines. They found that drugs called histone deacetylase (HDAC) inhibitors consistently slowed DIPG growth. Several of these drugs block histone deacetylases, a group of enzymes that regulate genes by removing chemical tags, called acetyl groups, from histone proteins. The scientists saw similar results when they genetically blocked individual histone deacetylases in the DIPG cells.
The scientists also analyzed the genes of each cell line. After reviewing the genetic and screening data they decided to focus on panobinostat, a drug designed to block multiple types of histone deacetylases. In petri dishes, they showed that panobinostat inhibited the growth of 12 out of 16 DIPG cell lines. When the scientists placed DIPG cells in the pons area of mice they found that systemic injections of panobinostat inhibited DIPG growth and extended survival.
“All roads lead to histones,” said Dr. Monje. “Our results support the idea that histone modifications are the keys to understanding and treating DIPG.”
Located in a cell’s nucleus, histones are protein complexes that act like genetic spools wound with genes on chromosomes. Enzymes, including histone deacetylases, influence how chromosomes wind around histones by adding or removing chemical tags. In turn, the tagging indirectly, or epigenetically, controls whether a gene on a chromosome will be used, or expressed, in that cell.
The scientists showed that panobistat may be effective at treating a variety of DIPG tumors. Approximately 80 percent of DIPG tumors have a specific mutation in a histone gene. This mutation, called H3K27M, blocks the ability of an enzyme called a methyltransferase from adding a chemical tag, called a methyl group, to the histone. Although the H3K27M mutation disrupts a different chemical tagging system, the scientists showed that panobinostat slowed the growth of a line of cells that had the mutation. Panobinostat also slowed the growth of DIPG cells that do not have that mutation.
Finally the scientists showed that panobinostat may work in combination with other treatments. Studying H3K27M cells that developed resistance to panobinostat over time, they showed that GSKJ4, a drug that blocks the removal of methyl groups from histones, slowed tumor growth. Combining panobistat and GSKJ4 appeared to slow growth further, suggesting the two compounds work synergistically.
“This may be a first step to finally improving the prognosis of this seemingly untreatable disease,” said Dr. Monje.
Dr. Monje, together with the National Cancer Institute-supported Pediatric Brain Tumor Consortium and Novartis, is planning to conduct clinical trials to test the safety and effectiveness of panobinostat for children with DIPG.


 

Friday, April 3, 2015

Pediatric Research: Number of childhood cancer survivors increasing ♦ New genetic clues to pediatric seizure disorders ♦ Element of surprise helps babies learn

The prevalence of childhood cancer survivors is estimated to have increased, and the majority of those who have survived five or more years beyond diagnosis may have at least one chronic health condition
Cognitive psychologists have demonstrated for the first time that babies learn new things by leveraging the core information they are born with. When something surprises a baby, like an object not behaving the way a baby expects it to, the baby not only focuses on that object, but ultimately learns more about it than from a similar yet predictable object.
Researchers have identified a new genetic mutation at the heart of a severe and potentially deadly seizure disorder found in infants and young children. The finding may help scientists unravel the complex biological mechanism behind these diseases. Epileptic seizures are the result of bursts of electrical activity in the brain caused when groups of neurons fire in an abnormal pattern.
A study of 4,500 U.S. children over 20 years has identified a single test that can predict which kids will become nearsighted by the eighth grade: a measure of their current refractive error. The refractive error, or eyeglasses prescription, results from mismatches in the size and optical power of the eye that lead to blurry vision

Friday, October 17, 2014

FDA Scientists Study Pediatric Brain Function

Study participants repeatedly press a lever on a large machine to make nickels slide out of a tube and drop into a cup. The coins pile up, but this activity in the Food and Drug Administration’s National Center for Toxicological Research (NCTR) laboratory at nearby Arkansas Children’s Hospital (ACH) isn’t a game of luck. It is a game that helps researchers compare important brain functions in children and animals—specifically their memory, attention, motivation, and time perception. The results provide the agency with important insights for the evaluation of the effects of pediatric drugs on psychological processes.
NCTR investigators have been studying brain function using this approach since 1988. They recruit human participants from ACH in Little Rock. The animal counterparts—monkeys—that play nearly identical games as the children are housed, cared for and tested at NCTR some 35 miles away.
So why are they doing this research? It is standard practice for the safety and effectiveness of new drugs to be tested in animals before these drugs are studied in humans. Unfortunately, it is sometimes difficult to predict how a new drug might affect brain function in humans based on the data obtained in animals. That’s because the types of tests given to assess brain function in animals often are different from the types of tests given to humans. By having animals and humans take exactly the same tests, researchers hope to be able to better predict the effects of drugs in humans using data obtained from animals.
It is hoped that the findings from these studies will help FDA, health care providers and parents make better informed decisions about medications for children—and to know more about how these medications might affect children’s brain function.
How the Testing Works
“We recruit a lot of our children from the general pediatric clinic. It’s a very broad sample and very diverse in terms of ethnicity, race, gender and age,” says John Chelonis, Ph.D., an NCTR research psychologist. Like all research involving human subjects, this study is subject to the many regulations designed to protect people of all ages who participate in clinical studies. “With human research,” Chelonis adds, “there are a lot of safeguards. If children decide they don’t want to play at any time, they can stop.”
The investigators have tested about 3,000 children since the lab opened. They see an average of eight to nine children per week, and the kids are always accompanied by consenting guardians.
Other NCTR staff train monkeys to participate in the research. The animals work for banana-flavored food pellets. “But they have to practice until they finally understand the rules of the games,” says Merle Paule, Ph.D., director of the Division of Neurotoxicology at NCTR. Some primates have been playing these games for almost 10 years. Once they learn the rules, which often takes months of trial and error performance, they can perform some games with accuracies of 95 percent or more.
“One of the important things about these games or tests is that they’re nonverbal,” says Paule. He explains that young kids don’t have language skills yet, and monkeys have none, and it’s the nonverbal nature of these tests, as opposed to traditional psychological tests, that makes more direct comparisons between the two groups possible.
Researchers study children who have attention deficit hyperactivity disorder (ADHD) and depression, and those who do not. “We try not to interfere with these kids’ treatment,” says Chelonis. “For instance, a lot of kids might be on their ADHD medication only during school days, and they’re off it on the weekends. So when we wanted to test the children when they were off their medication, we would typically schedule their sessions for the weekends when they were off of their medication.”
Researchers assess whether children’s responses vary in the presence or absence of medication and analyze the results based on gender and age. One of the tests that involves repeatedly pushing a lever on the behavior panel measures motivation. Children sit in front of the panel, which is positioned against a wall. They’re told to press one of the levers to get nickels. The first press releases one nickel. Children must press the lever 11 times for the second nickel (10 more than for the first nickel), 21 times for the third nickel, 31 times for the fourth nickel and so on, until the 10-minute game ends. The number of nickels earned depends on the strength of their motivation—how many times they press the lever.
Another game tests timing ability. For this, kids must hold one of the response levers down for at least 10 seconds, but not more than 14 seconds, to receive a nickel. It sounds simple. “But it’s a hard game,” says Chelonis. “It’s the cadence with which you count that gets you the nickel.” For this test, animals and kids tend to hold the lever down just long enough to meet the 10-second requirement. The timing ability of children with ADHD improves while on their medication. When children with ADHD are off their ADHD medication, they make more responses that are either too short or too long in duration compared to when they are on their ADHD medication.
What Researchers Hope to Accomplish
These FDA investigators are seeking to further validate their NCTR Operant Test Battery (OTB), the instrument they use to assess complex brain function in both children and monkeys.
They want to show:
  • How OTB task performance relates to IQ and other clinical tests that measure mental function in humans;
  • How OTB task performance relates to behavioral conditions such as ADHD, anxiety, and depression;
  • Whether OTB task performance is affected by drugs used to treat behavioral conditions such as ADHD; and
  • How children’s OTB performance compares to that obtained using animal models.
NCTR researchers have published many of their findings in a variety of scientific journals, including Experimental and Clinical Psychopharmacology, Behavioral Processes and Neurotoxicology and Teratology.
The value of animal models to predict clinical outcomes is important to FDA, Paule says. As researchers gain a better understanding of how animal OTB performance compares to human OTB performance, they’ll be able to develop better ways of using animal models to understand human behavior and better predict drug effects on human brain function. This eventually could help parents and medical professionals make more informed decisions about medication use and to understand the positive and negative effects that drugs may have on behavior.
FDA researchers are also studying the potential toxicity of general anesthetics and sedatives in children. Animal models suggest that a single episode of general anesthesia during critical stages of brain growth can cause lifelong deficits in brain function. The scientific community currently does not have enough human data to know whether this is a problem in the clinic, but it is suspected that prolonged or repeated exposures in children also could have cognitive consequences.
“Biology is basically the same across different species,” adds Paule, reflecting on NCTR’s comparative research. “Animals can do many things that we can do if we give them the right opportunity, and they can also show us a lot about drug effects if we can figure out how to look.”

FDA Scientists Study Pediatric Brain Function

Study participants repeatedly press a lever on a large machine to make nickels slide out of a tube and drop into a cup. The coins pile up, but this activity in the Food and Drug Administration’s National Center for Toxicological Research (NCTR) laboratory at nearby Arkansas Children’s Hospital (ACH) isn’t a game of luck. It is a game that helps researchers compare important brain functions in children and animals—specifically their memory, attention, motivation, and time perception. The results provide the agency with important insights for the evaluation of the effects of pediatric drugs on psychological processes.
NCTR investigators have been studying brain function using this approach since 1988. They recruit human participants from ACH in Little Rock. The animal counterparts—monkeys—that play nearly identical games as the children are housed, cared for and tested at NCTR some 35 miles away.
So why are they doing this research? It is standard practice for the safety and effectiveness of new drugs to be tested in animals before these drugs are studied in humans. Unfortunately, it is sometimes difficult to predict how a new drug might affect brain function in humans based on the data obtained in animals. That’s because the types of tests given to assess brain function in animals often are different from the types of tests given to humans. By having animals and humans take exactly the same tests, researchers hope to be able to better predict the effects of drugs in humans using data obtained from animals.
It is hoped that the findings from these studies will help FDA, health care providers and parents make better informed decisions about medications for children—and to know more about how these medications might affect children’s brain function.
How the Testing Works
“We recruit a lot of our children from the general pediatric clinic. It’s a very broad sample and very diverse in terms of ethnicity, race, gender and age,” says John Chelonis, Ph.D., an NCTR research psychologist. Like all research involving human subjects, this study is subject to the many regulations designed to protect people of all ages who participate in clinical studies. “With human research,” Chelonis adds, “there are a lot of safeguards. If children decide they don’t want to play at any time, they can stop.”
The investigators have tested about 3,000 children since the lab opened. They see an average of eight to nine children per week, and the kids are always accompanied by consenting guardians.
Other NCTR staff train monkeys to participate in the research. The animals work for banana-flavored food pellets. “But they have to practice until they finally understand the rules of the games,” says Merle Paule, Ph.D., director of the Division of Neurotoxicology at NCTR. Some primates have been playing these games for almost 10 years. Once they learn the rules, which often takes months of trial and error performance, they can perform some games with accuracies of 95 percent or more.
“One of the important things about these games or tests is that they’re nonverbal,” says Paule. He explains that young kids don’t have language skills yet, and monkeys have none, and it’s the nonverbal nature of these tests, as opposed to traditional psychological tests, that makes more direct comparisons between the two groups possible.
Researchers study children who have attention deficit hyperactivity disorder (ADHD) and depression, and those who do not. “We try not to interfere with these kids’ treatment,” says Chelonis. “For instance, a lot of kids might be on their ADHD medication only during school days, and they’re off it on the weekends. So when we wanted to test the children when they were off their medication, we would typically schedule their sessions for the weekends when they were off of their medication.”
Researchers assess whether children’s responses vary in the presence or absence of medication and analyze the results based on gender and age. One of the tests that involves repeatedly pushing a lever on the behavior panel measures motivation. Children sit in front of the panel, which is positioned against a wall. They’re told to press one of the levers to get nickels. The first press releases one nickel. Children must press the lever 11 times for the second nickel (10 more than for the first nickel), 21 times for the third nickel, 31 times for the fourth nickel and so on, until the 10-minute game ends. The number of nickels earned depends on the strength of their motivation—how many times they press the lever.
Another game tests timing ability. For this, kids must hold one of the response levers down for at least 10 seconds, but not more than 14 seconds, to receive a nickel. It sounds simple. “But it’s a hard game,” says Chelonis. “It’s the cadence with which you count that gets you the nickel.” For this test, animals and kids tend to hold the lever down just long enough to meet the 10-second requirement. The timing ability of children with ADHD improves while on their medication. When children with ADHD are off their ADHD medication, they make more responses that are either too short or too long in duration compared to when they are on their ADHD medication.
What Researchers Hope to Accomplish
These FDA investigators are seeking to further validate their NCTR Operant Test Battery (OTB), the instrument they use to assess complex brain function in both children and monkeys.
They want to show:
  • How OTB task performance relates to IQ and other clinical tests that measure mental function in humans;
  • How OTB task performance relates to behavioral conditions such as ADHD, anxiety, and depression;
  • Whether OTB task performance is affected by drugs used to treat behavioral conditions such as ADHD; and
  • How children’s OTB performance compares to that obtained using animal models.
NCTR researchers have published many of their findings in a variety of scientific journals, including Experimental and Clinical Psychopharmacology, Behavioral Processes and Neurotoxicology and Teratology.
The value of animal models to predict clinical outcomes is important to FDA, Paule says. As researchers gain a better understanding of how animal OTB performance compares to human OTB performance, they’ll be able to develop better ways of using animal models to understand human behavior and better predict drug effects on human brain function. This eventually could help parents and medical professionals make more informed decisions about medication use and to understand the positive and negative effects that drugs may have on behavior.
FDA researchers are also studying the potential toxicity of general anesthetics and sedatives in children. Animal models suggest that a single episode of general anesthesia during critical stages of brain growth can cause lifelong deficits in brain function. The scientific community currently does not have enough human data to know whether this is a problem in the clinic, but it is suspected that prolonged or repeated exposures in children also could have cognitive consequences.
“Biology is basically the same across different species,” adds Paule, reflecting on NCTR’s comparative research. “Animals can do many things that we can do if we give them the right opportunity, and they can also show us a lot about drug effects if we can figure out how to look.”

Friday, March 7, 2014

Severe Diarrheal Illness in Children Linked to Antibiotics Prescribed in Doctor’s Offices

CDC urges physicians to improve prescribing practices to reduce harm
The majority of pediatric Clostridium difficile infections, which are bacterial infections that cause severe diarrhea and are potentially life-threatening, occur among children in the general community who recently took antibiotics prescribed in doctor’s offices for other conditions, according to a new study by the Centers for Disease Control and Prevention published this week in Pediatrics.
The study showed that 71 percent of the cases of C. difficile infection identified among children aged 1 through 17 years were community-associated—that is, not associated with an overnight stay in a healthcare facility.  By contrast, two-thirds of C. difficile infections in adults are associated with hospital stays.
Among the community-associated pediatric cases whose parents were interviewed, 73 percent were prescribed antibiotics during the 12 weeks prior to their illness, usually in an outpatient setting such as a doctor’s office.  Most of the children who received antibiotics were being treated for ear, sinus, or upper respiratory infections. Previous studies show that at least 50 percent of antibiotics prescribed in doctor’s offices for children are for respiratory infections, most of which do not require antibiotics.
“Improved antibiotic prescribing is critical to protect the health of our nation’s children,” said CDC Director Tom Frieden, M.D., M.P.H.  “When antibiotics are prescribed incorrectly, our children are needlessly put at risk for health problems including C. difficile infection and dangerous antibiotic resistant infections.”

The blog is provided by Christian Lillis, Executive Director of the Peggy Lillis Memorial Foundation, who lost his mother to C. difficile infection.
The FY 2015 President’s Budget requests funding for CDC to improve outpatient antibiotic prescribing practices and protect patients from infections, such as those caused by C. difficile.  The CDC initiative aims to reduce outpatient prescribing by up to 20 percent and healthcare-associated C. difficile infections by 50 percent in five years.  A 50 percent reduction in healthcare-associated C. difficile infections could save 20,000 lives, prevent 150,000 hospitalizations, and cut more than $2 billion in healthcare costs.
C. difficile, which causes at least 250,000 infections in hospitalized patients and 14,000 deaths every year among children and adults, remains at all-time high levels.  According to preliminary CDC data, an estimated 17,000 children aged 1 through 17 years get C. difficile infections every year.  The Pediatrics study found that there was no difference in the incidence of C. difficile infection among boys and girls, and that the highest numbers were seen in white children and those between the ages of 12 and 23 months.
Taking antibiotics is the most important risk factor for developing C. difficile infections for both adults and children.  When a person takes antibiotics, beneficial bacteria that protect against infection can be altered or even eliminated for several weeks to months. During this time, patients can get sick from C. difficile picked up from contaminated surfaces or spread from a health care provider’s hands.
Although there have been significant improvements in antibiotic prescribing for certain acute respiratory infections in children, further improvement is greatly needed.  In addition, it is critical that parents avoid asking doctors to prescribe antibiotics for their children and that doctors follow prescribing guidelines.
“As both a doctor and a mom, I know how difficult it is to see your child suffer with something like an ear infection,” said Lauri Hicks, DO, director of CDC’s Get Smart: Know When Antibiotics Work program. “Antibiotics aren't always the answer. I urge parents to work with their child’s doctor to find the best treatment for the illness, which may just be providing symptom relief.”
For more information about the Get Smart program and improving antibiotic prescribing practices in doctor’s offices, visit http://www.cdc.gov/getsmart.
Real stories of C. difficile infectionin children: Two moms’ battles
Read the real life stories of two mothers who struggled with
C. difficile infection in their children on CDC’s Safe Healthcare Blog.  

The blog is provided by Christian Lillis, Executive Director of the Peggy Lillis Memorial Foundation, who lost his mother to C. difficile infection.